☆ 4.7 Meeting Abstract

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)-Pembrolizumab experimental arm (EA) primary results

JOURNAL OF CLINICAL ONCOLOGY (2021)

期刊

JOURNAL OF CLINICAL ONCOLOGY

卷 39, 期 3, 页码 -

出版社

LIPPINCOTT WILLIAMS & WILKINS

DOI: 10.1200/JCO.2021.39.3_suppl.8

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Oncology

Total Neoadjuvant Therapy (TNT) versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis

Shuang Liu, Ting Jiang, Lin Xiao, Shanfei Yang, Qing Liu, Yuanhong Gao, Gong Chen, Weiwei Xiao

Summary: Overall, total neoadjuvant therapy (TNT) may be more effective than standard treatment in improving the pathologic complete response rate. The TNT strategy may also improve disease-free survival and overall survival, and reduce the risk of distant metastasis.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial

Osama E. Rahma, Greg Yothers, Theodore S. Hong, Marcia M. Russell, Y. Nancy You, William Parker, Samuel A. Jacobs, Linda H. Colangelo, Peter C. Lucas, Marc J. Gollub, William A. Hall, Lisa A. Kachnic, Namrata Vijayvergia, Mark A. O'Rourke, Bryan A. Faller, Richard K. Valicenti, Tracey E. Schefter, Katherine M. Moxley, Radhika Kainthla, Philip J. Stella, Elin Sigurdson, Norman Wolmark, Thomas J. George

Summary: The study evaluated the addition of pembrolizumab during and after neoadjuvant chemoradiotherapy in rectal cancer patients, showing no significant differences in NAR score, pathological complete response rate, and other outcomes between the two groups.

JAMA ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Strategies to Optimize Treatment for Locally Advanced Rectal Cancer

Xiaoyu Hu, Zhuang Xue, Kewen He, Yaru Tian, Yu Chen, Mengyu Zhao, Jinming Yu, Jinbo Yue

Summary: Locally advanced rectal cancer (LARC) is a highly heterogeneous tumor group, and the risk of recurrence can be classified by MRI as low to very high according to ESMO guidelines. In the era of precision medicine, treatment decisions should be based on risk stratification. Not all LARC cases are appropriate for the traditional neoadjuvant sandwich strategy. Treatment modalities for LARC have evolved dramatically in recent years, with multiple clinical trials focused on optimizing strategies to improve outcomes for patients.

CANCERS (2023)

添加到收藏夹

Review Oncology

Role of MRI-based radiomics in locally advanced rectal cancer

Siyu Zhang, Mingrong Yu, Dan Chen, Peidong Li, Bin Tang, Jie Li

Summary: This review summarizes the applications, limitations and prospects of MRI-based radiomics in the treatment of locally advanced rectal cancer (LARC). Radiomics uses high-dimensional quantitative features extracted from medical imaging data to predict treatment response and prognosis, and has the potential to become an imaging biomarker for treatment prediction. However, there are still limitations and challenges in its current application.

ONCOLOGY REPORTS (2022)

添加到收藏夹

Review Biology

Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview

Andrea M. Guida, Bruno Sensi, Vincenzo Formica, Rolando M. D'Angelillo, Mario Roselli, Giovanna Del Vecchio Blanco, Piero Rossi, Gabriella T. Capolupo, Marco Caricato, Giuseppe S. Sica

Summary: Colorectal carcinoma is the second leading cause of cancer-related deaths, with rectal cancer accounting for approximately one third of new patients. The standard treatment for rectal cancer involves a multimodality approach focusing on local disease control. Total Neoadjuvant Therapy is an emerging strategy to reduce distant metastases and enhance local control, with ongoing studies evaluating its impact on oncological outcomes.

BIOLOGY DIRECT (2022)

添加到收藏夹

Article Oncology

Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial

Tomoko Yamazaki, Andrew J. Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X. Kiely, Amanda Hayman, David O'Brien, Rehan Ahmad, Jeffrey Manchio, Nathaniel Fox, Kayla McCarty, Michaela Phillips, Evelyn Brosnan, Gina Vaccaro, Rui Li, Miklos Simon, Eric Bernstein, Mary McCormick, Lena Yamasaki, Yaping Wu, Ashley Drokin, Trevor Carnahan, Yy To, William L. Redmond, Brian Lee, Jeannie Louie, Eric Hansen, Matthew C. Solhjem, Julie Cramer, Walter J. Urba, Michael J. Gough, Marka R. Crittenden, Kristina Young

Summary: The addition of galunisertib to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer improved the complete response rate to 32%, was well tolerated, and warrants further assessment in randomized trials.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

MRI-detected extramural vascular invasion (mrEMVI) as the best predictive factor to identify candidates to total neoadjuvant therapy in locally advanced rectal cancer

Paolo Massucco, Andrea P. Fontana, Annalisa Balbo Mussetto, Benedetta Desana, Andrea Ricotti, Federica Gonella, Michela Mineccia, Stefano Cirillo, Alessandro Ferrero

Summary: This study confirmed that magnetic resonance imaging-detected extramural vascular invasion (mrEMVI) is a powerful predictor of distant metastases (DM) in locally advanced rectal cancer (LARC). It should be routinely reported and considered during multidisciplinary care strategy planning.

JOURNAL OF SURGICAL ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long-term outcome in locally advanced rectal cancer

Ross K. McMahon, Sean M. O'Cathail, Harikrishnan Nair, Colin W. Steele, Jonathan J. Platt, Michael Digby, Alec C. McDonald, Paul G. Horgan, Campbell S. D. Roxburgh

Summary: This study aimed to explore the correlation between a novel MRI-based NAR score (mrNAR) and NAR score and evaluate its predictive value for the prognosis of rectal cancer patients. The results showed that mrNAR score was related to patients' survival rate and recurrence-free survival rate, and had independent predictive value, which was not completely consistent with NAR score. Therefore, mrNAR score may serve as an alternative endpoint for future neoadjuvant treatments that focus on organ preservation.

COLORECTAL DISEASE (2023)

添加到收藏夹

Article Oncology

Predicting Treatment Response of Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Amide Proton Transfer MRI Combined With Diffusion-Weighted Imaging

Weicui Chen, Liting Mao, Ling Li, Qiurong Wei, Shaowei Hu, Yongsong Ye, Jieping Feng, Bo Liu, Xian Liu

Summary: The combination of APTw and DWI can serve as a noninvasive biomarker for evaluating and identifying response to NCRT in patients with LARC.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A Nomogram for Predicting Pathological Complete Response to Neoadjuvant Chemoradiotherapy Using Semiquantitative Parameters Derived From Sequential PET/CT in Locally Advanced Rectal Cancer

Dae Hee Pyo, Joon Young Choi, Woo Yong Lee, Seong Hyeon Yun, Hee Cheol Kim, Jung Wook Huh, Yoon Ah Park, Jung Kyong Shin, Yong Beom Cho

Summary: The study evaluated the predictive value of semiquantitative volumetric parameters on predicting pathological complete response in rectal cancer patients who underwent neoadjuvant chemoradiotherapy and developed a reliable nomogram based on significant predictors derived from PET/CT. The nomogram showed better performance in selecting candidates for organ-sparing strategies compared to other predictive models that did not include PET/CT parameters, demonstrating its potential clinical utility in guiding treatment decisions for rectal cancer patients.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Neoadjuvant Therapy at Predominately Academic Centers between 2016-2020: An NCDB Analysis

Jason Liu, Colton Ladbury, Scott Glaser, Marwan Fakih, Andreas M. Kaiser, Yi-Jen Chen, Terence M. Williams, Arya Amini

Summary: This study retrospectively analyzed data from the National Cancer Database to determine the trends in the use of total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) in the United States from 2016 to 2020. It was found that the proportion of LARC patients receiving TNT increased significantly over time, with multiagent chemotherapy followed by long-course chemoradiation being the most common method. Factors such as age, gender, race, and disease stage were associated with the likelihood of receiving TNT.

CLINICAL COLORECTAL CANCER (2023)

添加到收藏夹

Review Oncology

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer

Huaqin Lin, Lei Wang, Xiaohong Zhong, Xueqing Zhang, Lingdong Shao, Junxin Wu

Summary: This meta-analysis comparing neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT) for locally advanced rectal cancer (LARC) found that NAC was superior to NACRT in terms of sphincter preservation rate, but noninferior in terms of other outcomes. Further validation is needed for these conclusions.

WORLD JOURNAL OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Prognostic and Predictive Biomarkers in Patients with Locally Advanced Rectal Cancer (LARC) Treated with Preoperative Chemoradiotherapy

Alfonso Martin-Carnicero, Enrique Ramalle-Gomara, Susana Rubio-Mediavilla, Martina Alonso-Lago, Miriam Zorrilla-Larraga, Isabel Manrique-Abos, Maria E. de las Heras-Duena, Ignacio M. Larrayoz, Alfredo Martinez

Summary: This retrospective study focuses on the clinical, analytical, and pathological parameters of locally advanced rectal cancer patients who received neoadjuvant chemoradiotherapy (CRT) and surgery. The study found that lower hemoglobin levels, lower lymphocyte/monocyte ratio, and higher platelet/lymphocyte ratio were associated with relapse. Additionally, the number of positive nodes after surgery and KRAS mutations were linked to worse prognosis.

JOURNAL OF CLINICAL MEDICINE (2022)

添加到收藏夹

Article Oncology

Total neoadjuvant treatment in locally advanced rectal cancer

Francesca De Felice, Vincenzo Tombolini, Enrico Cortesi

Summary: Locally advanced rectal cancer requires a multidisciplinary management involving neoadjuvant radiotherapy, conservative surgery, and chemotherapy. Recent studies have examined the potential benefits of altering the sequencing or intensity of the standard trimodal therapy components, with a focus on the clinical significance of total neoadjuvant treatment. More long-term results and prospective studies are needed to accurately determine the clinical benefits and establish the role of total neoadjuvant therapy in locally advanced rectal cancer.

TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Radiotherapy in the preoperative neoadjuvant treatment of locally advanced rectal cancer

Zhen Yu, Yuying Hao, Yuhua Huang, Ling Ling, Xigang Hu, Simiao Qiao

Summary: Radiotherapy and chemotherapy are effective treatments for locally advanced rectal cancer. New neoadjuvant treatment options need to be explored for better outcomes. Targeted drugs and immunologic agents have shown efficacy in advanced rectal cancer but have not been commonly used in neoadjuvant therapy for LARC patients.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Impact of Institutional Universal Microsatellite-Instability (MSI) Reflex Testing on Molecular Profiling Differences Between Younger and Older Patients with Colorectal Cancer

Ellery Altshuler, Aaron J. Franke, William Paul Skelton, Michael Feely, Yu Wang, Ji-Hyun Lee, Thomas Read, Krista Terracina, Xiang -Yang Lou, Yunfeng Dai, Thomas J. George

Summary: This study compared the tumor profiles of younger (<50 years) and older (>50 years) patients with colorectal cancer (CRC) after implementing universal reflex dMMR/MSI-H testing. Tumors of younger patients were less likely to have dMMR/MSI-H or BRAF mutation.

CLINICAL COLORECTAL CANCER (2023)

添加到收藏夹

Article Oncology

Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma

Azadeh Nasrazadani, Yujia Li, Yusi Fang, Osama Shah, Jennifer M. Atkinson, Joanna S. S. Lee, Priscilla F. McAuliffe, Rohit Bhargava, George Tseng, Adrian V. V. Lee, Peter C. Lucas, Steffi Oesterreich, Norman Wolmark

Summary: This study describes the clinicopathologic characteristics of mixed invasive ductal lobular carcinoma (mDLC) and finds that mDLC is clinically more similar to invasive lobular carcinoma (ILC) than invasive ductal carcinoma (IDC). Successful breast-conserving surgery rates after neoadjuvant chemotherapy are higher in mDLC patients compared to ILC patients. The metastatic patterns of mDLC show characteristics of both IDC and ILC.

BRITISH JOURNAL OF CANCER (2023)

添加到收藏夹

Article Oncology

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue-Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer Jr, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis, Malgorzata Nowicka, Sanne de Haas, Mark Basik

Summary: In patients with residual invasive breast cancer, T-DM1 reduces the risk of disease recurrence or death compared to trastuzumab. The efficacy of T-DM1 is independent of HER2 expression level and immune activation.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Review Oncology

The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes

Sayali S. Onkar, Neil M. Carleton, Peter C. Lucas, Tullia C. Bruno, Adrian V. Lee, Dario A. A. Vignali, Steffi Oesterreich

Summary: Breast cancer is a diverse disease with different subtypes, and recent advances have provided new insights into the complex interactions between tumor and immune cells. While immunotherapy has shown limited promise for breast cancer, this review aims to identify opportunities for tailored immunotherapy agents based on the specific features of each breast cancer subtype.

CANCER DISCOVERY (2023)

添加到收藏夹

Article Oncology

Call to action: overcoming enrollment disparities in cancer clinical trials with modernized eligibility criteria

Andrea N. Riner, Devon C. Freudenberger, Kelly M. Herremans, Vignesh Vudatha, Daniel W. Neal, Thomas J. George, Jose G. Trevino

Summary: Traditional clinical trial eligibility criteria limit the study population and worsen enrollment disparities. This study aimed to evaluate the implementation of modernized eligibility criteria guidelines in pancreatic cancer clinical trials. A total of 198 trials conducted in the United States between January 1, 2014, and December 31, 2017, were assessed for guideline compliance. Improvements were observed in allowing patients with HIV history, prior cancer, or concurrent and/or stable cancer to participate. However, overall compliance with modernized criteria remains poor, highlighting the need for stakeholders to update protocols and scrutinize restrictive eligibility criteria.

JNCI CANCER SPECTRUM (2023)

添加到收藏夹

Correction Oncology

Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment (Mar, 10.1038/s43018-023-00527-w, 2023)

Sayali Onkar, Jian Cui, Jian Zou, Carly Cardello, Anthony R. Cillo, Mostofa Rafid Uddin, April Sagan, Marion Joy, Hatice U. Osmanbeyoglu, Katherine L. Pogue-Geile, Priscilla F. McAuliffe, Peter C. Lucas, George C. Tseng, Adrian V. Lee, Tullia C. Bruno, Steffi Oesterreich, Dario A. A. Vignali

NATURE CANCER (2023)

添加到收藏夹

Article Oncology

Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment

Sayali Onkar, Jian Cui, Jian Zou, Carly Cardello, Anthony R. Cillo, Mostofa Rafid Uddin, April Sagan, Marion Joy, Hatice U. Osmanbeyoglu, Katherine L. Pogue-Geile, Priscilla F. McAuliffe, Peter C. Lucas, George C. Tseng, Adrian V. V. Lee, Tullia C. Bruno, Steffi Oesterreich, Dario A. A. Vignali

Summary: Using single-cell and high-dimensional profiling, this study investigates the immune biology of estrogen receptor-positive (ER+) breast cancer in women with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). The results show that macrophages, rather than T cells, are the dominant immune cells infiltrating the tumor bed in both IDC and ILC. Furthermore, an interplay between macrophages and T cells is associated with longer disease-free survival in IDC but not ILC.

NATURE CANCER (2023)

添加到收藏夹

Article Oncology

Prognosis and Treatment Outcomes of Bone Metastasis in Gallbladder Adenocarcinoma: A SEER-Based Study

Kriti Gera, Doga Kahramangil, Graeme A. Fenton, Daniela Martir, Diana N. Rodriguez, Zohaib Ijaz, Rick Y. Lin, Sherise C. Rogers, Brian H. Ramnaraign, Thomas J. George, Young-Rock Hong, Steven J. Hughes, Ibrahim Nassour, Ilyas Sahin

Summary: This study analyzed the SEER database to investigate metastatic gallbladder adenocarcinoma patients and found that bone metastasis is an independent prognostic factor for unfavorable survival outcomes in the younger age group. Chemotherapy treatment is associated with extended survival in all patients.

CANCERS (2023)

添加到收藏夹

Article Oncology

Effects of Clinical and Tumor Characteristics on Survival in Patients with Hepatocellular Carcinoma with Bone Metastasis

Muhammet Ozer, Suleyman Yasin Goksu, Rick Y. Lin, Ruveyda Ayasun, Doga Kahramangil, Sherise C. Rogers, Jesus C. Fabregas, Brian H. Ramnaraign, Thomas J. George, Michael Feely, Roniel Cabrera, Sergio Duarte, Ali Zarrinpar, Ilyas Sahin

Summary: This study analyzed a cohort of 170,576 patients with hepatocellular carcinoma and found a bone metastasis rate of 3.1%. The results showed that HCC patients with well-differentiated tumors, receiving chemotherapy, younger age, no major comorbidities, and treated at academic facilities had better overall survival.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2023)

添加到收藏夹

Article Chemistry, Analytical

Gold Nanoparticle-Based Microfluidic Chips for Capture and Detection of Circulating Tumor Cells

Valber A. Pedrosa, Kangfu Chen, Thomas J. George, Z. Hugh Fan

Summary: Liquid biopsy has been developed for diagnosing and monitoring cancer. However, there is still room for improvement in capturing circulating tumor cells (CTCs). In this study, we integrated gold nanoparticles with a microfluidic platform to develop an efficient CTC detection system, which achieved CTC capture within 120 min. Our method was optimized and demonstrated high efficiency (90% ± 3.2%) in capturing CTCs from pancreatic tumor cell lines and patients with metastatic pancreatic cancer.

BIOSENSORS-BASEL (2023)

添加到收藏夹

Article Oncology

Ethical Considerations of Biopsies in Early-Stage Pancreatic Cancer

Riley P. Bohan, Andrea N. Riner, Kelly M. Herremans, Thomas J. George, Steven J. Hughes, Lauren B. Solberg

Summary: The standard of care for resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC) has evolved to include neoadjuvant treatment before surgical resection. Current guidelines recommend obtaining histologic tissue diagnosis through endoscopic ultrasound fine-needle aspiration before neoadjuvant therapy, which is different from guidelines discouraging delay in surgical resection for a biopsy.

JCO ONCOLOGY PRACTICE (2023)

添加到收藏夹

Article Oncology

Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations

Thomas J. George, Tara L. Lin, Tricia Adrales Bentz, Stefan Grant, Collette M. Houston, Melissa A. Nashawati, Bhanu Pappu, Helen Peck, Alex Zafirovski, Kimberly Kerstann, Patricia Lorusso, Anne Schnatterly, Janie Hofacker, Kendra Cameron, Hailey Honeycutt, Theresa L. Werner

Summary: The COVID-19 pandemic had a significant impact on oncology clinical trials, resulting in a substantial decrease in interventional treatment trial accruals in 2020 and 2021 compared to pre-pandemic figures in 2019. However, hospitals were able to implement best practices to ensure patient safety and continue clinical trials despite the challenges posed by the pandemic.

JNCI CANCER SPECTRUM (2023)

添加到收藏夹

Meeting Abstract Oncology

Association of stromal tumor infiltrating lymphocytes (sTILs) in pretreatment biopsies in different molecular subtypes of HER2+/ER+ breast cancer: Assessment of NRG Oncology/NSABP B-52

Katherine L. Pogue-Geile, Sai K. Maley, Rim S. Kim, Ying Wang, Roberto Salgado, Corey Lipchik, Huichen Feng, Reena S. Cecchini, Samuel A. Jacobs, Ashok Srinivasan, Eleftherios Terry Mamounas, Charles E. Geyer, Priya Rastogi, C. Kent Osborne, Soonmyung Paik, Norman Wolmark, Peter C. Lucas, Mothaffar Rimawi

CANCER RESEARCH (2023)

添加到收藏夹

Meeting Abstract Oncology

Uncovering molecular heterogeneity of mixed ductal and lobular carcinoma using digital spatial profiling

Osama Shiraz Shah, Azadeh Nasrazadani, Jennifer M. Atkinson, Celina Kleer, Priscilla F. McAuliffe, Rohit Bhargava, Jorge Reis-Filho, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich

CANCER RESEARCH (2023)

添加到收藏夹

Meeting Abstract Oncology

Feasibility metric outcomes: A nurse-led intervention to identify and manage undiagnosed type 2 diabetes in patients with newly diagnosed cancer

Lisa Scarton, Tarah Nelson, Yingwei Yao, Shavondra Huggins, Ara Jo, LaToya J. O'Neal, Thomas J. George, Juan M. Munoz-Pena, Merry J. Markham, Martina C. Murphy, Jonathan A. Chatzkel, Sherise Rogers

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.